Cellyan Biotechnology (HKPD) director Wu Jingyan submits initial SEC Form 3

Rhea-AI Filing Summary

Cellyan Biotechnology Co., Ltd director Wu Jingyan has filed an initial Form 3, which is the SEC’s statement of beneficial ownership for company insiders. This filing establishes Wu’s status as a director and provides a baseline disclosure of holdings, with no transactions reported in this data.

Key Terms

Form 3, beneficial ownership, reporting person

3 terms

Form 3 regulatory

"has filed an initial Form 3, which is the SEC’s statement"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"initial Form 3, which is the SEC’s statement of beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"The Form 3 filing records Wu Jingyan as a director and reporting person"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/08/2026 - 02:24 PM Accepted by SEC EDGAR 06/08/2026 - 02:23 PM Learn about SEC filing dates

FAQ

What does the Cellyan Biotechnology (HKPD) Form 3 filing by Wu Jingyan mean?

The Form 3 filing records Wu Jingyan as a director of Cellyan Biotechnology and provides an initial statement of beneficial ownership. It establishes a baseline disclosure of Wu’s position as an insider, without reporting any specific share transactions in this data.

Does the Cellyan Biotechnology (HKPD) Form 3 show any stock transactions by Wu Jingyan?

No stock transactions appear in this Form 3 data for Wu Jingyan. Form 3 is primarily an initial ownership statement; trades are typically reported later on Forms 4 or 5 when they occur.

What role does Wu Jingyan have at Cellyan Biotechnology (HKPD) according to the Form 3?

According to the Form 3, Wu Jingyan is a director of Cellyan Biotechnology. Being a director makes Wu an insider, subject to ongoing ownership and transaction reporting obligations under SEC rules.

How is beneficial ownership reporting started for Cellyan Biotechnology (HKPD) insiders?

Beneficial ownership reporting for insiders like directors starts with a Form 3 filing. This initial form identifies the insider and sets a baseline for future disclosures of trades or changes in ownership on Forms 4 and 5.

Why is Form 3 important for Cellyan Biotechnology (HKPD) investors?

Form 3 is important because it identifies who qualifies as an insider at Cellyan Biotechnology. It establishes the starting point for tracking insider ownership and any later trades that may be disclosed on subsequent SEC forms.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wu Jingyan

(Last) (First) (Middle)

65 GRASSMAN PL.

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellyan Biotechnology Co., Ltd [ HKPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jingyan Wu	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)